Amylyx Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
AMLX$30.21+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Product revenue, net | $— | $87,371 |
| Operating expenses: | ||
| Cost of sales | — | 5,953 |
| Cost of sales - inventory impairment and loss on firm purchase commitments | — | 118,680 |
| Acquired in-process research and development | — | 36,203 |
| Research and development | 90,404 | 104,084 |
| Selling, general and administrative | 62,887 | 114,331 |
| Restructuring expenses | — | 22,851 |
| Total operating expenses | 153,291 | 402,102 |
| Loss from operations | (153,291) | (314,731) |
| Other income, net: | ||
| Interest income | 9,302 | 13,809 |
| Other expense, net | (700) | (1,214) |
| Total other income, net | 8,602 | 12,595 |
| Loss before income taxes | (144,689) | (302,136) |
| Provision (benefit) for income taxes | 46 | (393) |
| Net loss | $(144,735) | $(301,743) |
| Net loss per share - basic and diluted | $(1.53) | $(4.43) |
| Weighted-average shares used in computing net loss per share - basic and diluted | 94,565,567 | 68,142,158 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.